{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:22:17Z","timestamp":1785432137871,"version":"3.56.0"},"reference-count":78,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background: Viral rebound (VR), the resurgence of detectable human immunodeficiency virus (HIV) viral loads (&gt; 50 copies\/mL) after suppression, remains a challenge for individuals on antiretroviral therapy (ART) in South Africa, despite free access to treatment.\n\nAim: This systematic review aimed to determine the prevalence of HIV VR and its contributing factors among individuals on ART.\n\nSetting: This is a systematic review study, it relies primarily on secondary data, and it does not have a physical setting.\n\nMethod: This study is conducted in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Cochrane methodology, and the study was registered with PROSPERO (ID: CRD42024524121). Data were sourced from PubMed, EBSCOhost and Scopus, yielding 89 684 articles. After screening in Rayyan, 23 articles met the inclusion criteria. The risk of bias was assessed using the Joanna Briggs Institute\u2019s (JBI\u2019s) appraisal tool.\n\nResults: Viral rebound varies across different populations. Contributing factors included biological, genetic, demographic, socio-economic and structural elements, as well as incarceration, missed appointments, lifestyle behaviours, travel, multiple sexual partners, ART regimen, age and clinical management. Poor ART adherence emerged as a key driver.\n\nConclusion: Human immunodeficiency virus viral rebound results from a combination of biological, social and treatment-related factors, with non-adherence to ART being a major contributor. The study highlights the need for improved adherence strategies to reduce VR.\n\nContribution: This review enhances the understanding of HIV VR prevalence and its contributing factors, while also providing recommendations to mitigate these factors.<\/jats:p>","DOI":"10.4102\/jphia.v16i1.1324","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:14:49Z","timestamp":1755184489000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and factors associated with HIV viral rebound in individuals on ART: A systematic review study"],"prefix":"10.4102","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3768-7950","authenticated-orcid":false,"given":"Lindokuhle","family":"Ndlazi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003hsr719","id-type":"ROR","asserted-by":"publisher"}],"name":"Sefako Makgatho Health Sciences University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-8212","authenticated-orcid":false,"given":"Mathildah","family":"Mokgatle","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003hsr719","id-type":"ROR","asserted-by":"publisher"}],"name":"Sefako Makgatho Health Sciences University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2148-7439","authenticated-orcid":false,"given":"Lindiwe","family":"Cele","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003hsr719","id-type":"ROR","asserted-by":"publisher"}],"name":"Sefako Makgatho Health Sciences University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6459-9065","authenticated-orcid":false,"given":"Raikane","family":"Seretlo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003hsr719","id-type":"ROR","asserted-by":"publisher"}],"name":"Sefako Makgatho Health Sciences University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Mpolya E. A prospective study of predictors of HIV viral load rebound in an HIV hyperendemic rural population of KwaZulu-Natal, South Africa. PAMJ-One Health. 2023;11:13. https:\/\/doi.org\/10.11604\/pamj-oh.2023.11.13.40381","DOI":"10.11604\/pamj-oh.2023.11.13.40381"},{"key":"#cr-split#-ref1.1","unstructured":"Simbayi L, Zuma K, Zungu N, et al. South African National HIV prevalence, incidence, behaviour and communication survey, 2017: Towards achieving the UNAIDS 90-90-90 targets. Cape Town: HSRC Press"},{"key":"#cr-split#-ref1.2","unstructured":"2019 [cited 2025 Jul 04]. Available from: https:\/\/repository.hsrc.ac.za\/handle\/20.500.11910\/15052"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hirasen K, Fox MP, Hendrickson CJ, et al. HIV treatment outcomes among patients initiated on antiretroviral therapy pre and post-universal test and treat guidelines in South Africa. Ther Clincal Risk Manag. 2020;16:169\u2013180. https:\/\/doi.org\/10.2147\/TCRM.S227290","DOI":"10.2147\/TCRM.S227290"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"G\u00fcnthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society\u2013USA panel. JAMA. 2016;316:191\u2013210. https:\/\/doi.org\/10.1001\/jama.2016.8900","DOI":"10.1001\/jama.2016.8900"},{"key":"ref4","unstructured":"Eggleton JS, Nagalli S. Highly Active Antiretroviral Therapy (HAART). Treasure Island, FL: StatPearls Publishing; 2023."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Geretti AM, Smith C, Haberl A, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13:927\u2013936. https:\/\/doi.org\/10.1177\/135965350801300707","DOI":"10.1177\/135965350801300707"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Maina E, Mureithi H, Adan A, et al. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. Int J Infect Dis. 2020;97:151\u2013158. https:\/\/doi.org\/10.1016\/j.ijid.2020.05.097","DOI":"10.1016\/j.ijid.2020.05.097"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Min S, Gillani FS, Aung S, et al. Evaluating HIV viral rebound among persons on suppressive antiretroviral treatment in the era of \u2018undetectable equals untransmittable (U= U)\u2019. Open Forum Infect Dis. 2020;7(12):ofaa529.","DOI":"10.1093\/ofid\/ofaa529"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Baumann KE, Phillips AL, Arya M. Overlap of HIV and low health literacy in the southern USA. Lancet HIV. 2015;2:e269. https:\/\/doi.org\/10.1016\/S2352-3018(15)00121-6","DOI":"10.1016\/S2352-3018(15)00121-6"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gaston GB, Alleyne-Green B. The impact of African Americans\u2019 beliefs about HIV medical care on treatment adherence: A systematic review and recommendations for interventions. AIDS Behav. 2013;17:31\u201340. https:\/\/doi.org\/10.1007\/s10461-012-0323-x","DOI":"10.1007\/s10461-012-0323-x"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Geter A, Herron AR, Sutton MY. HIV-related stigma by healthcare providers in the United States: A systematic review. AIDS Patient Care STDs. 2018;32:418\u2013424. https:\/\/doi.org\/10.1089\/apc.2018.0114","DOI":"10.1089\/apc.2018.0114"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Kassa D, Gebremichael G, Alemayehu Y, et al. Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia. AIDS Res Ther. 2013;10:1\u201312. https:\/\/doi.org\/10.1186\/1742-6405-10-18","DOI":"10.1186\/1742-6405-10-18"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Horter S, Thabede Z, Dlamini V, et al. \u2018Life is so easy on ART, once you accept it\u2019: Acceptance, denial and linkage to HIV care in Shiselweni, Swaziland. Soc Sci Med. 2017;176:52\u201359. https:\/\/doi.org\/10.1016\/j.socscimed.2017.01.006","DOI":"10.1016\/j.socscimed.2017.01.006"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Kahabuka MS, Woldeamanuel Y, Mbelele PM, et al. HIV viral suppression and risk of viral rebound in patients on antiretroviral therapy: A two-year retrospective cohort study in Northern Tanzania. BMC Infect Dis. 2024;24:390. https:\/\/doi.org\/10.1186\/s12879-024-09161-y","DOI":"10.1186\/s12879-024-09161-y"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Liu T, Chambers LC, Hansen B, et al. Risk of HIV viral rebound in the era of universal treatment in a multicenter sample of persons with HIV in primary care. Open Forum Infect Dis. 2023;10(6):ofad257.","DOI":"10.1093\/ofid\/ofad257"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Craw JA, Beer L, Tie Y, et al. Viral rebound among persons with diagnosed HIV who achieved viral suppression, United States. J Acquir Immune Defic Syndr. 2020;84:133\u2013140. https:\/\/doi.org\/10.1097\/QAI.0000000000002321","DOI":"10.1097\/QAI.0000000000002321"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Cromer D, Pinkevych M, Rasmussen TA, et al. Modeling of antilatency treatment in HIV: What is the optimal duration of antiretroviral therapy-free HIV remission? J Virol. 2017;91(24):e01395-17. https:\/\/doi.org\/10.1128\/JVI.01395-17","DOI":"10.1128\/JVI.01395-17"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Deeks SG, Archin N, Cannon P, et al. Research priorities for an HIV cure: International AIDS society global scientific strategy 2021. Nat Med. 2021;27:2085\u20132098. https:\/\/doi.org\/10.1038\/s41591-021-01590-5","DOI":"10.1038\/s41591-021-01590-5"},{"key":"ref18","unstructured":"Chinuoya M, Rikhotso R, Ngunyulu RN, et al. Some mix it with other things to smoke\u2019: Perceived use and misuse of ARV by street thugs in Tshwane District, South Africa. Afr J Phys Health Edu Recreat Dance. 2014;1(1):113\u2013126."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Hermans LE, Carmona S, Nijhuis M, et al. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study. PLoS Med. 2020;17:e1003037. https:\/\/doi.org\/10.1371\/journal.pmed.1003037","DOI":"10.1371\/journal.pmed.1003037"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Hans L, Cassim N, Sarang S, et al. HIV viral load testing in the South African public health setting in the context of evolving ART guidelines and advances in technology, 2013\u20132022.c Diagnostics. 2023;13:2731. https:\/\/doi.org\/10.3390\/diagnostics13172731","DOI":"10.3390\/diagnostics13172731"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Zhou S, Cluver L, Shenderovich Y, et al. Uncovering ART adherence inconsistencies: An assessment of sustained adherence among adolescents in South Africa. J Int AIDS Soc. 2021;24(10):e25832. https:\/\/doi.org\/10.1002\/jia2.25832","DOI":"10.1002\/jia2.25832"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010;8:336\u2013341. https:\/\/doi.org\/10.1016\/j.ijsu.2010.02.007","DOI":"10.1016\/j.ijsu.2010.02.007"},{"key":"ref23","unstructured":"Chandler J, Cumpston M, Li T, et al. Cochrane handbook for systematic reviews of interventions. Hoboken, NJ: Wiley; 2019."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Aamer HA, McClure J, Ko D, et al. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment. PLoS Pathog. 2020;16(8):e1008791. https:\/\/doi.org\/10.1371\/journal.ppat.1008791","DOI":"10.1371\/journal.ppat.1008791"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Armenia D, Di Carlo D, Cozzi-Lepri A, et al. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. Antivir Ther. 2019;24(5):321\u2013331. https:\/\/doi.org\/10.3851\/IMP3309","DOI":"10.3851\/IMP3309"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Burch LS, Smith CJ, Anderson J, et al. Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: Cross-sectional and longitudinal analyses. Lancet Public Health. 2016;1(1):e26\u2013e36. https:\/\/doi.org\/10.1016\/S2468-2667(16)30002-0","DOI":"10.1016\/S2468-2667(16)30002-0"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Cole B, Lambrechts L, Boyer Z, et al. Extensive characterization of HIV-1 reservoirs reveals links to plasma viremia before and during analytical treatment interruption. Cell Rep. 2022;39(4):110739. https:\/\/doi.org\/10.1016\/j.celrep.2022.110739","DOI":"10.1016\/j.celrep.2022.110739"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"De Scheerder MA, Vrancken B, Dellicour S, et al. HIV rebound is predominantly fueled by genetically identical viral expansions from diverse reservoirs. Cell Host Microbe. 2019;26(3):347\u2013358. https:\/\/doi.org\/10.1016\/j.chom.2019.08.003","DOI":"10.1016\/j.chom.2019.08.003"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Dessie ZG, Zewotir T, Mwambi H, North D. Modeling viral suppression, viral rebound and state-specific duration of HIV patients with CD4 count adjustment: Parametric multistate frailty model approach. Infect Dis Ther. 2020;9:367\u2013388. https:\/\/doi.org\/10.1007\/s40121-020-00296-4","DOI":"10.1007\/s40121-020-00296-4"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Gebreselassie HM, Kraus D, Fux CA, et al. Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV cohort study. HIV Med. 2017;18(8):564\u2013572. https:\/\/doi.org\/10.1111\/hiv.12491","DOI":"10.1111\/hiv.12491"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Giacomelli A, Micheli V, Cattaneo D, Mancon A, Gervasoni C. Multidrug-resistant HIV viral rebound during early syphilis: A case report. BMC Infect Dis. 2020;20:1\u20135. https:\/\/doi.org\/10.1186\/s12879-020-04999-4","DOI":"10.1186\/s12879-020-04999-4"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Hayashi R, Hara A, Iwasa Y. Viral rebound occurrence immediately after drug discontinuation involving neither drug resistance nor latent reservoir. J Theor Biol. 2024;582:111767. https:\/\/doi.org\/10.1016\/j.jtbi.2024.111767","DOI":"10.1016\/j.jtbi.2024.111767"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Jones TP, Lampe FC, Arenas-Pinto A, et al. Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: Cross-sectional and longitudinal analyses. HIV Med. 2022;23(3):209\u201326. https:\/\/doi.org\/10.1111\/hiv.13156","DOI":"10.1111\/hiv.13156"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Kang-Birken SL, El-Sayed D, Prichard J. HIV viral rebound due to a possible drug\u2013drug interaction between elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide and calcium-containing products: Report of 2 cases. J Int Assoc Provid AIDS Care. 2019;18:2325958218821653. https:\/\/doi.org\/10.1177\/2325958218821653","DOI":"10.1177\/2325958218821653"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Kankou JM, Bouchaud O, Lele N, et al. Factors associated with virological rebound in HIV-positive Sub-Saharan Migrants living in France after traveling back to their native country: ANRS-VIHVO 2006\u20132009 study. J Immigr Minor Health. 2019;21:1342\u20131348. https:\/\/doi.org\/10.1007\/s10903-019-00864-y","DOI":"10.1007\/s10903-019-00864-y"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Ladak F, Socias E, Nolan S, et al. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting. Antivir Ther. 2019;24(1):19\u201325. https:\/\/doi.org\/10.3851\/IMP3265","DOI":"10.3851\/IMP3265"},{"key":"ref38","unstructured":"Megasari NL, Wijaksana IK. Factors affecting HIV viral load of antiretroviral therapy experienced and na\u00efve individuals residing in Bali, Indonesia. Mal J Med Health Sci. 2023;19:111\u2013115."},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Mujugira A, Celum C, Tappero JW, Ronald A, Mugo N, Baeten JM. Younger age predicts failure to achieve viral suppression and virologic rebound among HIV-1-infected persons in serodiscordant partnerships. AIDS Res Hum Retroviruses. 2016;32(2):148\u2013154. https:\/\/doi.org\/10.1089\/aid.2015.0296","DOI":"10.1089\/aid.2015.0296"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Offersen R, Yu WH, Scully EP, et al. HIV antibody Fc N-linked glycosylation is associated with viral rebound. Cell Rep. 2020;33(11):108502. https:\/\/doi.org\/10.1016\/j.celrep.2020.108502","DOI":"10.1016\/j.celrep.2020.108502"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Opoku S, Sakyi SA, Ayisi-Boateng NK, et al. Factors associated with viral suppression and rebound among adult HIV patients on treatment: A retrospective study in Ghana. AIDS Res Ther. 2022;19(1):21. https:\/\/doi.org\/10.1186\/s12981-022-00447-2","DOI":"10.1186\/s12981-022-00447-2"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Palmer A, Gabler K, Rachlis B, et al. Viral suppression and viral rebound among young adults living with HIV in Canada. Medicine. 2018;97(22):e10562. https:\/\/doi.org\/10.1097\/MD.0000000000010562","DOI":"10.1097\/MD.0000000000010562"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Small W, Milloy MJ, McNeil R, Maher L, Kerr T. Plasma HIV-1 RNA viral load rebound among people who inject drugs receiving antiretroviral therapy (ART) in a Canadian setting: An ethno-epidemiological study. AIDS Res Ther. 2016;13:1\u20132. https:\/\/doi.org\/10.1186\/s12981-016-0108-9","DOI":"10.1186\/s12981-016-0108-9"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"St\u00f6hr W, Dunn DT, Arenas-Pinto A, et al. Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy. AIDS. 2016;30(17):2617\u20132624. https:\/\/doi.org\/10.1097\/QAD.0000000000001206","DOI":"10.1097\/QAD.0000000000001206"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Rosen JG, Ssekubugu R, Chang LW, et al. Temporal dynamics and drivers of durable HIV viral load suppression and persistent high-and low-level viraemia during Universal Test and Treat scale-up in Uganda: A population-based study. J Int AIDS Soc. 2024;27:e26200. https:\/\/doi.org\/10.1002\/jia2.26200","DOI":"10.1002\/jia2.26200"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Bansi LK, Benzie AA, Phillips AN, et al. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS (London, England). 2008;22:349\u2013356. https:\/\/doi.org\/10.1097\/QAD.0b013e3282f4709a","DOI":"10.1097\/QAD.0b013e3282f4709a"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Bridges B, Collaboration COC, Benoit AC, et al. A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada. Antivir Ther. 2017;22:325\u2013335. https:\/\/doi.org\/10.3851\/IMP3114","DOI":"10.3851\/IMP3114"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Grabowski MK, Patel EU, Nakigozi G, et al. Prevalence and predictors of persistent human immunodeficiency virus viremia and viral rebound after universal test and treat: A population-based study. J Infect Dis. 2021;223:1150\u20131160. https:\/\/doi.org\/10.1093\/infdis\/jiab021","DOI":"10.1093\/infdis\/jiab021"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Vallejo A, Molina-Pinelo S, De Felipe B, et al. Brief report: Toll-like receptor 9-1635A\/G polymorphism is associated with HIV-1 rebound after four weeks of interruption of antiretroviral therapy. J Acquir Immune Defic Syndr. 2020;85:252\u2013256. https:\/\/doi.org\/10.1097\/QAI.0000000000002437","DOI":"10.1097\/QAI.0000000000002437"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Thorball CW, Borghesi A, Bachmann N, et al. Host genomics of the HIV-1 reservoir size and its decay rate during suppressive antiretroviral treatment. J Acquir Immune Defic Syndr. 2020;85:517\u2013524. https:\/\/doi.org\/10.1097\/QAI.0000000000002473","DOI":"10.1097\/QAI.0000000000002473"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Childs T, Shingadia D, Goodall R, et al. Outcomes after viral load rebound on first-line antiretroviral treatment in children with HIV in the UK and Ireland: An observational cohort study. Lancet HIV. 2015;2:e151\u2013e158. https:\/\/doi.org\/10.1016\/S2352-3018(15)00021-1","DOI":"10.1016\/S2352-3018(15)00021-1"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Boucoiran I, Albert AY, Tulloch K, et al. Human immunodeficiency virus viral load rebound near delivery in previously suppressed, combination antiretroviral therapy\u2013treated pregnant women. Obstetr Gynecol. 2017;130:497\u2013501. https:\/\/doi.org\/10.1097\/AOG.0000000000002133","DOI":"10.1097\/AOG.0000000000002133"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Rock AE, DeMarais PL, Vergara-Rodriguez PT, et al. HIV-1 virologic rebound due to coadministration of divalent cations and bictegravir. Infect Dis Ther. 2020;9:691\u2013696. https:\/\/doi.org\/10.1007\/s40121-020-00307-4","DOI":"10.1007\/s40121-020-00307-4"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Kumar S, Rao P, Earla R, et al. Drug\u2013drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Metab Toxicol. 2015;11:343\u2013355. https:\/\/doi.org\/10.1517\/17425255.2015.996546","DOI":"10.1517\/17425255.2015.996546"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Iniesta-Naval\u00f3n C, Franco-Miguel JJ, Gasc\u00f3n-C\u00e1novas JJ, et al. Effect of drug interactions involving antiretroviral drugs on viral load in HIV population. Eur J Hosp Pharm. 2016;23:241\u2013243. https:\/\/doi.org\/10.1136\/ejhpharm-2015-000670","DOI":"10.1136\/ejhpharm-2015-000670"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Barnabas RV, Webb EL, Weiss HA, et al. The role of coinfections in HIV epidemic trajectory and positive prevention: A systematic review and meta-analysis. AIDS. 2011;25:1559\u20131573.","DOI":"10.1097\/QAD.0b013e3283491e3e"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Acchioni C, Sandini S, Acchioni M, et al. Co-Infections and superinfections between HIV-1 and other human viruses at the cellular level. Pathogens. 2024;13:349. https:\/\/doi.org\/10.3390\/pathogens13050349","DOI":"10.3390\/pathogens13050349"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Study AC-C. Elevated risk of viral rebound on ART in migrants living in France: Role of socioeconomic factors. Antivir Ther. 2019;24:541\u2013552. https:\/\/doi.org\/10.3851\/IMP3339","DOI":"10.3851\/IMP3339"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"L\u00f3pez JD, Qiao Q, Presti RM, et al. The impact of neighborhood socioeconomic status on retention in care and viral suppression among people living with HIV. AIDS Care. 2022;34:1383\u20131389. https:\/\/doi.org\/10.1080\/09540121.2022.2040724","DOI":"10.1080\/09540121.2022.2040724"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Wohl DA, Rosen DL. Inadequate HIV care after incarceration: Case closed. Lancet HIV. 2018;5:e64\u2013e65. https:\/\/doi.org\/10.1016\/S2352-3018(17)30210-2","DOI":"10.1016\/S2352-3018(17)30210-2"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Westergaard RP, Kirk GD, Richesson DR, et al. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53:725\u2013731. https:\/\/doi.org\/10.1093\/cid\/cir491","DOI":"10.1093\/cid\/cir491"},{"key":"ref62","unstructured":"Hao J. Navigating missed visits in HIV primary care: Exploring risk factors associated with missed visits. Birmingham: The University of Alabama at Birmingham; 2023."},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112\u20131118. https:\/\/doi.org\/10.1086\/378301","DOI":"10.1086\/378301"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Tanner Z, Lachowsky N, Ding E, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect Dis. 2016;16:1\u201311. https:\/\/doi.org\/10.1186\/s12879-016-1926-z","DOI":"10.1186\/s12879-016-1926-z"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Wynn A, Sileo KM, Schmarje Crockett K, et al. Associations between alcohol use, antiretroviral therapy use, and viral load suppression among people living with HIV in rural central Uganda. AIDS Behav. 2024;28:2205\u20132215. https:\/\/doi.org\/10.1007\/s10461-024-04299-x","DOI":"10.1007\/s10461-024-04299-x"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Apenteng OO, Ismail NA. Modelling the impact of international travellers on the trend of HIV epidemic. In: Proceedings of the world congress on engineering and computer science. 2014.","DOI":"10.1007\/978-94-017-7236-5_27"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA. 2008;105:16725\u201316730. https:\/\/doi.org\/10.1073\/pnas.0804192105","DOI":"10.1073\/pnas.0804192105"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Bruce D, Harper GW, Suleta K, et al. Sexual risk behavior and risk reduction beliefs among HIV-positive young men who have sex with men. AIDS Behav. 2013;17:1515\u20131523. https:\/\/doi.org\/10.1007\/s10461-012-0155-8","DOI":"10.1007\/s10461-012-0155-8"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Achappa B, Madi D, Bhaskaran U, et al. Adherence to antiretroviral therapy among people living with HIV. N Am J Med Sci. 2013;5(3):220. https:\/\/doi.org\/10.4103\/1947-2714.109196","DOI":"10.4103\/1947-2714.109196"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Maggiolo F, Di Filippo E, Comi L, et al. Reduced adherence to antiretroviral therapy is associated with residual low-level viremia. Pragmat Obs Res. 2017;8:91\u201397. https:\/\/doi.org\/10.2147\/POR.S127974","DOI":"10.2147\/POR.S127974"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Castagna A, Muccini C, Galli L, et al. Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). J Antimicrob Chemother. 2019;74:2039\u20132046. https:\/\/doi.org\/10.1093\/jac\/dkz138","DOI":"10.1093\/jac\/dkz138"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Robertson M, Laraque F, Mavronicolas H, et al. Linkage and retention in care and the time to HIV viral suppression and viral rebound\u2013New York City. AIDS Care. 2015;27:260\u2013267. https:\/\/doi.org\/10.1080\/09540121.2014.959463","DOI":"10.1080\/09540121.2014.959463"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, et al. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. J Antimicrob Chemother. 2018;73:3460\u20133470. https:\/\/doi.org\/10.1093\/jac\/dky350","DOI":"10.1093\/jac\/dky350"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Joseph Davey D, Abrahams Z, Feinberg M, et al. Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa. Int J STD AIDS. 2018;29:603\u2013610. https:\/\/doi.org\/10.1177\/0956462417748859","DOI":"10.1177\/0956462417748859"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Adams JW, Marshall BD, Salleh NAM, et al. Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs. Drug Alcohol Depend. 2020;206:107670. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107670","DOI":"10.1016\/j.drugalcdep.2019.107670"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Dhairyawan R, Okhai H, Hill T, et al. Differences in HIV clinical outcomes amongst heterosexuals in the United Kingdom by ethnicity. AIDS. 2021;35:1813\u20131821. https:\/\/doi.org\/10.1097\/QAD.0000000000002942","DOI":"10.1097\/QAD.0000000000002942"}],"container-title":["Journal of Public Health in Africa"],"original-title":[],"link":[{"URL":"https:\/\/publichealthinafrica.org\/index.php\/jphia\/article\/view\/1324\/2209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T09:18:37Z","timestamp":1755681517000},"score":1,"resource":{"primary":{"URL":"https:\/\/publichealthinafrica.org\/index.php\/jphia\/article\/view\/1324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/jphia.v16i1.1324","relation":{},"ISSN":["2038-9922","2038-9930"],"issn-type":[{"value":"2038-9922","type":"print"},{"value":"2038-9930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"a1324"}}